Zobrazeno 1 - 7
of 7
pro vyhledávání: '"John A. Ligon"'
Autor:
Aiman J. Faruqi, John A. Ligon, Paul Borgman, Seth M. Steinberg, Toni Foley, Lauren Little, Crystal L. Mackall, Daniel W. Lee, Terry J. Fry, Haneen Shalabi, Jennifer Brudno, Bonnie Yates, Lekha Mikkilineni, James Kochenderfer, Nirali N. Shah
Publikováno v:
Blood Advances. 6:6040-6050
Cancer outcomes with chemotherapy are inferior in patients of minority racial/ethnic groups and those with obesity. Chimeric antigen receptor (CAR) T-cell therapy has transformed outcomes for relapsed/refractory hematologic malignancies, but whether
Autor:
Haneen Shalabi, Haiying Qin, Angela Su, Bonnie Yates, Pamela L. Wolters, Seth M. Steinberg, John A. Ligon, Sara Silbert, Kniya DéDé, Mehdi Benzaoui, Sophia Goldberg, Sooraj Achar, Dina Schneider, Shilpa A. Shahani, Lauren Little, Toni Foley, John C. Molina, Sandhya Panch, Crystal L. Mackall, Daniel W. Lee, Christopher D. Chien, Marie Pouzolles, Mark Ahlman, Constance M. Yuan, Hao-Wei Wang, Yanyu Wang, Jon Inglefield, Mary Anne Toledo-Tamula, Staci Martin, Steven L. Highfill, Gregoire Altan-Bonnet, David Stroncek, Terry J. Fry, Naomi Taylor, Nirali N. Shah
Publikováno v:
Blood. 140:451-463
Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-cells is limited by antigen modulation, which may be overcome with combinatorial targeting. Building upon our experiences targeting CD19 and CD22 in B-cell acute
Autor:
Elizabeth M. Holland, Bonnie Yates, Alex Ling, Constance M. Yuan, Hao-Wei Wang, Maryalice Stetler-Stevenson, Michael LaLoggia, John C. Molina, Daniel A. Lichtenstein, Daniel W. Lee, John A. Ligon, Haneen Shalabi, Mark A. Ahlman, Nirali N. Shah
Publikováno v:
Blood Advances. 6:2167-2182
Chimeric antigen receptor (CAR) T cells effectively eradicate medullary B-cell acute lymphoblastic leukemia (B-ALL) and can traffic to and clear central nervous system (CNS) involvement. CAR T-cell activity in non-CNS extramedullary disease (EMD) has
Autor:
John A. Ligon, Abigail Fry, Jacqueline Y. Maher, Toni Foley, Sara Silbert, Bonnie Yates, Veronica Gomez-Lobo, Lori Wiener, Nirali N. Shah
Publikováno v:
Transplantation and cellular therapy. 28(9)
Chimeric antigen receptor (CAR) T-cells serve to overcome chemotherapeutic resistance and have been proven to be highly effective in B-cell hematologic malignancies. Although initial use has been in patients with multiply relapsed/refractory disease,
Publikováno v:
Frontiers in immunology. 13
Advances from novel adoptive cellular therapies have yet to be fully realized for the treatment of children and young adults with solid tumors. This review discusses the strategies and preliminary results, including T-cell, NK-cell and myeloid cell-b
Autor:
Jack F. Shern, Ching C. Lau, Young K. Song, Beverly A. Teicher, Shintaro Iwata, Paul S. Meltzer, Javed Khan, Uma Mudunuri, Daniel Catchpoole, Yuelin J. Zhu, Udayan Guha, Jay S. Wunder, Marc Ladanyi, Sivasish Sindiri, Marielle E. Yohe, David Milewski, Irene L. Andrulis, John A. Ligon, Nicolas J. Llosa, Xinyu Wen, Rimas J. Orentas, Manoj Tyagi, Igor B. Kuznetsov, Daniel Leino, Yue Qi, Hsien-Chao Chou, Heather Magnan, Jeetendra Kumar, Sushma Nagaraj, Andrew S. Brohl, Vineela Gangalapudi, Jack R. Collins, Jun Wei, Brian Turpin, Katherine E. Masih, Hue V. Reardon, Silvia Regina Caminada de Toledo
Publikováno v:
Cell reports
SUMMARY We perform an immunogenomics analysis utilizing whole-transcriptome sequencing of 657 pediatric extra-cranial solid cancer samples representing 14 diagnoses, and additionally utilize transcriptomes of 131 pediatric cancer cell lines and 147 n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6c063562b8bfce44878bf4842ae4b86
https://hdl.handle.net/10453/156052
https://hdl.handle.net/10453/156052
Autor:
Jon Inglefield, Javed Khan, Nirali N. Shah, Katherine E. Masih, Veronique Nussenblatt, Lauren Little, Maura Manion, Amanda K. Ombrello, Zahin Islam, Haneen Shalabi, John A. Ligon, Bonnie Yates
Publikováno v:
Pediatr Blood Cancer
Serious bacterial infections (SBI) can lead to devastating complications with CD19 CAR T cells and cytokine release syndrome (CRS). Little is known about consequences of and risk factors for SBI with novel CAR T-cell constructs or with CRS complicate